Vaccon 2019 vaccine quality and safety forum and sub forum of the 12th China Biological Industry Conference

Vaccon 2019 vaccine quality and safety forum and the first round notice of the sub forum of the 12th China biological industry congress June 10-11, 2019 Guangzhou Baiyun International Conference Center November 11, 2018 State Administration of market supervision and Administration issued the vaccine management law of the people's Republic of China (Draft for comments) It aims to strengthen vaccine supervision with the strictest standards, strictest supervision, strictest punishment and strictest accountability, and implement the strictest management system for vaccines in all aspects of development, production, circulation and vaccination In just 30 to 40 years, China's vaccine industry has developed rapidly, and vaccine research and development has been in the forefront of the world The rapid development is bound to easily ignore many imperfections Changchun Changsheng vaccine incident has exposed many problems such as quality, safety and circulation that cannot be ignored, which has sounded a profound alarm for the industry "Vaccines concern people's health, public health and national security." How to establish a perfect clinical trial evaluation mechanism? How to optimize production process and improve quality control standard? How to realize the whole process quality assurance and traceability of vaccine cold chain? As an important part of the 12th China biological industry conference, vaccon vaccine quality and safety forum is scheduled to be held in Guangzhou on June 10-11, 2019, "safety" will become the theme of this forum The forum will invite more than 30 domestic and foreign experts and scholars in the field of vaccines, senior managers of vaccine enterprises, leaders of regulatory departments, etc the guests will cover the upstream and downstream of the vaccine industry chain, and conduct extensive and in-depth technical and standard discussions around regulatory supervision, safety review, production process, cold chain circulation Vaccon 2019 is looking forward to working with more vaccine professionals to build a solid quality and safety system and rebuild the confidence of China's vaccine industry! Chairman of the Forum: Gao Fu, President of China Society of bioengineering, academician of Chinese Academy of Sciences, director of China Center for Disease Control and prevention organizer: China Society of bioengineering organizer: BMAP Shanghai Shangtu Information Consulting Co., Ltd brand new special subject section vaccine development safety under the regulation of June 10: strengthening the progress of vaccine management and supervision implementation in China Towards the world: who pre certification of vaccines and its future trend of immunization planning development and technical standardization of vaccine related standards in China International pharmacopoeia for the quality and technical requirements of biological products vaccine update the quality control of polysaccharide structure analysis and identification of polysaccharide vaccine case study: key points of safety and quality control of polyvalent vaccine round table discussion: (1) education and communication -- how to rebuild the confidence of domestic vaccine? (2) Round table discussion: from the perspective of production, education and research: Innovation of vaccine safety science, vaccine technology and production safety in line with the global standards on June 11, ensuring the quality, safety and effectiveness of vaccine products from the source of product design Quality comes from the application of design and process analysis technology in the development of vaccine technology Innovation technology of cell matrix serum-free culture technology for vaccine production Research progress of new generation safer and more effective vaccine development leading practice of new vaccine analysis, detection, separation and purification process purification Safety supervision of China's vaccine clinical development and long-term effect evaluation update of current new vaccine preclinical safety evaluation strategy and existing problems case study: clinical design and evaluation in vaccine clinical development difficulties of vaccine clinical trial quality control under GCP analysis of senior managers of business development department, R & D department and Quality Department of participating group vaccine and biological products company Gao Fu, a distinguished research institution, scientists' regulations of major universities, as well as the senior management of cro and CMO, the supplier of biotechnology and quality analysis equipment, has been confirmed as a guest Wang Junzhi, President of China Society of bioengineering, academician of Chinese Academy of Sciences and director of China Center for disease control and prevention, and Wang Junzhi, chief expert of biological product inspection of China Academy of food and drug control Zhang Yonghui, an expert from the State Drug Administration, an Kang, director of Guangdong CDC, Shi Li, chairman of Hualan biology, Chao Shoubai, chief executive officer of Shanghai Zerun Biotechnology Co., Ltd., Zhang Yi, chief operating officer of kangxinuo biology Co., Ltd., Li qihan, chairman of Yisheng biopharmaceutical Co., Ltd., and director of Institute of medical biology, Chinese Academy of Medical Sciences Zou Quanming, Chen Ling, director of the national immune biological products engineering technology research center of the Army Medical University, Wang Bin, first president of Guangzhou Institute of biomedicine and health, Chinese Academy of Sciences, Professor of the school of basic medicine, Fudan University, Shao Hui, head of the National Engineering Laboratory of therapeutic vaccines, Zheng Haifa, President and CEO of Yisheng Biological Pharmaceutical Co., Ltd, Peng Tao, vice president of Shenzhen Kangtai Biological Products Co., Ltd., general manager and chief scientist of Beijing minhai Biological Technology Co., Ltd, Gauden galea, chairman of Guangdong South China United Vaccine Development Institute Co., Ltd., Yang Xiaoming, representative of the World Health Organization in China, Fouad atouf, chief scientist of the vaccine project of the national "863" program and chairman of Sinopharm, Jeffrey Ulmer, vice president of global biological products of the United States Pharmacopoeia Committee, vice president of preclinical development of GSK vaccine Peng Tao, chairman and chief scientist of Guangdong South China United Vaccine Development Institute Co., Ltd., provides limited free tickets (only for vaccine research and production enterprise personnel) Tickets include: two-day conference tickets, conference materials; catering, accommodation for yourself); if you are a vaccine technical service provider and other people concerned about vaccine industry, now you can enjoy a thousand yuan discount (tickets include conference tickets, conference materials, two-day conference buffet lunch; other accommodation for yourself) If you want to apply for the conference, please scan the QR code directly below, click "I want to register" to become a participant (the free ticket needs to be reviewed by the Organizing Committee); become a sponsor of the forum, provide you with a variety of forms such as keynote speech, product display, cooperation invitation, etc to display vaccine safety solutions in an all-round way! Sponsorship quota, limited opening! For more information, please contact the organizing committee! Tel: +8618017939885 email: vaccon@bmapglobal.com website: www.bmapglobal.com/vaccon2019